#China #Shanghai #Kexing Biopharm #CPHI China #PMEC China

Kexing Biopharm Makes Waves at CPHI and PMEC China 2026

From June 16 to 18, 2026, the bustling city of Shanghai hosted the CPHI (Convention on Pharmaceutical Ingredients) and PMEC (Pharmaceutical Machinery & Equipment Convention) at the New International Expo Center. This significant event provided Kexing Biopharm (688136.SH) an invaluable platform to showcase its innovative drug programs and extensive portfolio aimed at international markets. The company's participation culminated in receiving a prestigious award for research and development innovation, demonstrating its commitment to advancing healthcare solutions.

Showcasing Innovation and Winning Awards

At the heart of Kexing Biopharm's presentation was a range of advanced pharmaceuticals targeting pressing health challenges. The innovative lineup included renowned oncology products and treatments for autoimmune disorders and metabolic diseases. Leading medications featured extensive discussions, including albumin-bound paclitaxel, bevacizumab, infliximab, enzalutamide, aflibercept, liraglutide, and semaglutide. This strategic showcase mirrored the company’s dedication to addressing critical health needs and highlighted its research-driven approach.

In addition to the groundbreaking pharmaceuticals, Kexing Biopharm revealed several noteworthy projects from its global R&D portfolio, such as GB18 for cancer-related cachexia, GB19/GB26 targeting systemic lupus erythematosus, and GB10 for ophthalmology applications. Furthermore, advancements in two Phase III clinical trials – the long-acting GC formulation and GB05 (an inhalable interferon solution) – captured significant interest from attendees, emphasizing the company's innovative prowess in drug development.

The award for innovation in research and development underscores Kexing Biopharm's unwavering focus on technological advancements and practical solutions that meet global health demands. This honor, bestowed by industry experts and event organizers, evaluated several facets including strategic clinical transformations and the overall impact of Kexing’s innovations on the pharmaceutical market.

Strengthening Global Partnerships

Kexing Biopharm's presence at CPHI and PMEC also provided ample opportunities for networking and collaboration. The commercial development team was integral in participating in key forums and roundtable discussions focusing on international pharmaceutical expansion. Topics such as the global marketing of Chinese biopharmaceuticals were at the forefront, allowing the Kexing team to present its successful platform and glean insights crucial for refining international strategies.

On the evening of June 15, Kexing Biopharm hosted a reception honoring clients and partners from across various countries. The atmosphere fostered thoughtful dialogues about market dynamics, cooperative prospects, and future strategic planning, laying the groundwork for fruitful partnerships built on mutual trust and win-win collaborations.

The CPHI event proved to be a strategic platform for Kexing Biopharm, enabling the company to highlight its strengths and connect with the worldwide pharmaceutical community. As the company aims to solidify its global footprint, it is committed to collaborating with international partners to bring forth high-quality products to a broader market. With the successful showcasing at CPHI and PMEC, Kexing Biopharm is set on a promising trajectory toward future advancements and innovations in the healthcare sector.